Related Experiment Video
Updated: Jul 9, 2025

Diagnosis and Surgical Treatment of Human Brucellar Spondylodiscitis
Published on: May 23, 2021
Faciocervical Group B Streptococcal Necrotising Fasciitis: a Multidisciplinary Approach to Management
Theodore Paul Pezas1, Joep Fernando2, Norma Timoney3
1Department of Paediatric Plastic Surgery, Evelina London Children's Hospital, London, UK theodorepezas@doctors.org.uk.
Neonatal necrotising fasciitis caused by Group B Streptococcus (GBS) is rare and life-threatening. Early surgical debridement and multidisciplinary scar management are crucial for survival and optimal outcomes.
Area of Science:
- Neonatal surgery
- Infectious diseases
- Dermatology
Background:
- Neonatal necrotising fasciitis is a rare, severe infection.
- Group B Streptococcus (GBS) is the common causative agent.
- Facial and cervical infections often originate from the oral cavity.
Observation:
- A male neonate presented with severe faciocervical necrotising fasciitis.
- The condition was secondary to Streptococcus agalactiae (GBS).
- Multiple surgical debridements were required.
Findings:
- The soft tissue defect healed with negative pressure therapy and dermal substitute.
- Skin grafting was avoided due to prematurity.
- Intensive scar therapy resulted in a favorable cosmetic outcome without functional limitation.
Implications:
- Early surgical intervention is critical for life-threatening GBS infections.
- A multidisciplinary approach, including early scar management, is essential.
- Negative pressure therapy and dermal substitutes offer viable reconstructive options.
More Related Videos
04:01Indocyanine Green-Guided Intraoperative Imaging to Facilitate Video-Assisted Retroperitoneal Debridement for Treating Acute Necrotizing Pancreatitis
Published on: September 8, 2022
07:22A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
Published on: March 14, 2025
Related Concept Videos
Flail Chest-II
Assessment:
1. Clinical Evaluation:
History:
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Tonsillitis II: Management